Study finds increase in cannabis-related disorders among pregnant women post legalization

Share this article The revenue for CB-012 is expected to reach an annual total of $11 mn by 2039 in the US based off GlobalData’s

Nek­tar Ther­a­peu­tics said its for­mer part­ner Eli Lil­ly had pre­sent­ed “er­ro­neous da­ta” for its atopic der­mati­tis drug be­fore break­ing off a $400 mil­lion al­liance. Where­as

No­var­tis is in dis­cus­sions to buy Cy­to­ki­net­ics, the Wall Street Jour­nal re­port­ed Mon­day, send­ing the biotech’s stock $CYTK soar­ing near­ly 15%. The deal could be